| NCT ID | NCT02113644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht University Medical Center |
| Condition | Cardiovascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2014-04 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2014-04 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of Prevent CardioKids is to evaluate to what extend disturbed vascular function markers are already present in children of different weight categories and whether these are age dependent. Also differences - and relationships - between vascular function measurements and plasma biomarkers between lean and overweight/obese children will be compared.
Eligibility Criteria
Inclusion Criteria: * Participation in the COACH program * Aged between 6 and 18 years (at time of inclusion) * Overweight or obesity according to IOTF criteria In order to be eligible to participate in the control group, a subject must meet all of the following criteria: * Aged between 6 and 18 years * Normal weight according to the IOTF criteria * Undergo surgery for elective reasons Exclusion Criteria: * Retarded children * Children suffering from: * Inflammatory diseases: auto-immune diseases, inflammatory bowel diseases, hepatitis, dermatitis, nephritis, pancreatitis, gastro-enteritis, vasculitis, salpingitis, arthritis, osteomyelitis, myositis, ear-nose-throat infections * Allergic diseases: asthma, eczema, hay fever, food allergies * Oncologic diseases * Cystic fibrosis * Type 1 diabetes mellitus * Congenital metabolic diseases * Malnourished children
Contact & Investigator
Anita Vreugdenhil, dr.
PRINCIPAL INVESTIGATOR
Maastricht University Medical Center
Frequently Asked Questions
Who can join the NCT02113644 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02113644 currently recruiting?
Yes, NCT02113644 is actively recruiting participants. Contact the research team at a.vreugdenhil@mumc.nl for enrollment information.
Where is the NCT02113644 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT02113644 clinical trial?
NCT02113644 is sponsored by Maastricht University Medical Center. The principal investigator is Anita Vreugdenhil, dr. at Maastricht University Medical Center. The trial plans to enroll 240 participants.